On November 3, 2026 Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, reported that Sanofi notified Nurix of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As a result of Sanofi’s decision, Nurix does not anticipate receiving any of the future development, regulatory and commercial milestone payments or royalties for which it has been eligible under the collaboration with respect to the SAR448272 program. Nurix remains eligible to receive milestone payments and royalties with respect to its other previously announced licensed programs developed under the collaboration agreement that Sanofi may at its discretion develop further into clinical candidates. Today’s announcement does not change Nurix’s recently issued cash runway guidance, with cash, cash equivalents and marketable securities of $1.1 billion as of August 31, 2026, sufficient to fund operations into the second half of 2029.
"While today’s news is disappointing, Nurix remains in a strong position, with a substantial cash runway, three clinical-stage programs across our wholly owned and partnered portfolio, and an exciting preclinical pipeline," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. "Bexobrutideg, our lead BTK degrader program partnered with Roche, is advancing in a Phase 3 trial in patients with chronic lymphocytic leukemia; our wholly owned CBL-B inhibitor NX-1607 is advancing in multiple Phase 1b cohorts for patients with lung cancer, colon cancer, prostate cancer, and melanoma; and our IRAK4 degrader for rheumatoid arthritis, GS-6791/NX-0479 is advancing through Phase 1 trials with our partner Gilead."
About the Nurix/Sanofi Collaboration
Under the 2019 collaboration agreement, Nurix deployed its proprietary DEL-AI drug discovery platform to identify novel agents that utilize E3 ligases to induce the degradation of specified proteins. In 2025, Sanofi exercised its license extension option for two programs targeting transcription factors for the treatment of autoimmune/inflammatory diseases including an undisclosed target and STAT6. For both programs, Nurix retains the option to co-develop and co-promote in the United States following demonstration of clinical proof of concept.
(Press release, Nurix Therapeutics, NOV 3, 2026, View Source [SID1234674097])